Partnerships Picks For GeNeuro’s MS Antibody
GeNeuro’s CEO And His Mission To Bring Anti-HERV Benefits To MS Patients
Executive Summary
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
You may also be interested in...
GeNeuro, Servier 'Disappointed' With Mid-Way Phase IIb Multiple Sclerosis Study
GeNeuro and partner Servier voiced disappointment over results seen midway through a Phase IIb trial studying a potential cause of multiple sclerosis - but insisted the trial will continue for the final 6 months.
The Power Of AI To Map The Patient Journey
Mapping the patient journey uncovers a wealth of insights into care, diagnosis and intervention. The onset of advanced analytics tools and sensors now augment the pharma industry’s understanding of the challenges of traversing health care systems. Layering AI into the mapping process not only has the power to provide insights into the current clinical pathway, it can be used to predict and intervene in clinical care.
Parkinson’s Disease: Ripe For A Rethink
Despite decades of R&D, there are no disease modifying therapies on the market for Parkinson’s disease, and few efficacious products for non-motor symptoms. Clinical setbacks have been rife but breakthroughs in diagnostics and a better understanding of disease pathology brings hope for the future. In Vivo speaks to some of those responsible for bringing innovation to the field.